CIK 0001831828 · Large accelerated filer
Vera Therapeutics, Inc.
Sign in to watch- Ticker
- VERA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 812744449
- Phone
- 650-770-0077
- Business address
- 2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE, CA, 94005
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,334,142
- in 2 filings, $1.3M under 10b5-1 plans
Net −$1,334,142. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 98 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-18 | Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR | Grant or award · Stock Option (right to buy) | +21,500 | 21,500 | ||
| 2025-02-18 | Turner William D. Chief Development Officer | Grant or award | +22,500 | 22,500 | ||
| 2025-02-18 | Turner William D. Chief Development Officer | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2025-02-18 | Brenner Robert Chief Medical Officer | Grant or award | +26,900 | 27,474 | ||
| 2025-02-18 | Brenner Robert Chief Medical Officer | Grant or award · Stock Option (right to buy) | +53,800 | 53,800 | ||
| 2025-02-18 | Grant Sean CHIEF FINANCIAL OFFICER | Grant or award | +26,900 | 93,237 | ||
| 2025-02-18 | Grant Sean CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (right to buy) | +53,800 | 53,800 | ||
| 2025-02-18 | Fordyce Marshall PRESIDENT AND CEO | Grant or award | +80,750 | 224,353 | ||
| 2025-02-18 | Fordyce Marshall PRESIDENT AND CEO | Grant or award · Stock Option (right to buy) | +161,500 | 161,500 | ||
| 2025-02-18 | JOHNSON DAVID LEE Chief Operating Officer | Grant or award | +26,900 | 26,900 | ||
| 2025-02-18 | JOHNSON DAVID LEE Chief Operating Officer | Grant or award · Stock Option (right to buy) | +53,800 | 53,800 | ||
| 2025-01-08 | Fordyce Marshall PRESIDENT AND CEO | Option exercise 10b5-1 | +9,975 | $2.90 | $29K | 153,578 |
| 2025-01-08 | Fordyce Marshall PRESIDENT AND CEO | Sale 10b5-1 | −9,975 | $41.53 | $414K | 143,603 |
| 2025-01-08 | Fordyce Marshall PRESIDENT AND CEO | Option exercise 10b5-1 | +5,650 | $2.90 | $16K | 149,253 |
| 2025-01-08 | Fordyce Marshall PRESIDENT AND CEO | Sale 10b5-1 | −5,650 | $42.03 | $237K | 143,603 |
| 2025-01-08 | Fordyce Marshall PRESIDENT AND CEO | Option exercise 10b5-1 | +1,875 | $2.90 | $5K | 145,478 |
| 2025-01-08 | Fordyce Marshall PRESIDENT AND CEO | Sale 10b5-1 | −1,875 | $42.00 | $79K | 143,603 |
| 2025-01-08 | Fordyce Marshall PRESIDENT AND CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −15,625 | 610,926 | ||
| 2025-01-08 | Fordyce Marshall PRESIDENT AND CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,875 | 609,051 | ||
| 2024-12-19 | Fordyce Marshall PRESIDENT AND CEO | Option exercise 10b5-1 | +57,661 | $2.90 | $167K | 143,603 |
Page 6 of 17 · 321 trades